Fifth Third Bancorp
DYN icon

Fifth Third Bancorp’s Dyne Therapeutics DYN Stock Holding History

Fifth Third Bancorp’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
75,859
+21,630
+40% +$402K ﹤0.01% 1371
2026
Q1 		$983K Buy
+54,229
New +$935K ﹤0.01% 1650

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fifth Third Bancorp's DYN Position: Q2 2026 in Review

Fifth Third Bancorp increased its Dyne Therapeutics (DYN) stake by 40% in Q2 2026, buying an estimated $402K and bringing the position to 75,859 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

Fifth Third Bancorp first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Fifth Third Bancorp held 75,859 shares of Dyne Therapeutics worth $1.68M as of Q2 2026.
  • Fifth Third Bancorp bought 21,630 Dyne Therapeutics shares in Q2 2026, an estimated $402K.
  • Dyne Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #1371 holding.
  • Fifth Third Bancorp first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.